Dafna Capital Management LLC Blueprint Medicines Corp Transaction History

Dafna Capital Management LLC

$389 Million
Q3 2024

A detailed history of Dafna Capital Management LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Dafna Capital Management LLC holds 121,763 shares of BPMC stock, worth $11.5 Million. This represents 2.89% of its overall portfolio holdings.

Number of Shares

121,763

Previous 104,763 16.23%

Holding current value

$11.5 Million

Previous $11.3 Million 0.29%

% of portfolio

2.89%

Previous 2.89%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$84.1 - $120.5 $1.43 Million - $2.05 Million	17,000 Added 16.23%	121,763 $11.3 Million
Q2 2024 Aug 14, 2024	SELL	$85.18 - $108.78 $170,360 - $217,560	-2,000 Reduced 1.87%	104,763 $11.3 Million
Q1 2024 May 15, 2024	SELL	$73.17 - $99.79 $299,997 - $409,139	-4,100 Reduced 3.7%	106,763 $10.1 Million
Q4 2023 Feb 14, 2024	SELL	$43.96 - $92.84 $6.1 Million - $12.9 Million	-138,658 Reduced 55.57%	110,863 $10.2 Million
Q3 2023 Nov 14, 2023	SELL	$46.9 - $66.0 $93,800 - $132,000	-2,000 Reduced 0.8%	249,521 $12.5 Million
Q2 2023 Aug 14, 2023	SELL	$42.2 - $66.37 $409,930 - $644,718	-9,714 Reduced 3.72%	251,521 $15.9 Million
Q3 2022 Nov 14, 2022	SELL	$49.93 - $77.7 $2,246 - $3,496	-45 Reduced 0.02%	261,235 $17.2 Million
Q2 2022 Aug 15, 2022	BUY	$45.23 - $70.15 $678,450 - $1.05 Million	15,000 Added 6.09%	261,280 $13.2 Million
Q1 2022 May 16, 2022	BUY	$54.1 - $110.08 $2.13 Million - $4.33 Million	39,369 Added 19.03%	246,280 $15.7 Million
Q3 2021 Nov 15, 2021	SELL	$80.98 - $109.47 $80,980 - $109,470	-1,000 Reduced 0.48%	206,911 $21.3 Million
Q1 2021 May 17, 2021	BUY	$90.71 - $108.28 $90,710 - $108,280	1,000 Added 0.48%	207,911 $20.2 Million
Q4 2020 Feb 16, 2021	SELL	$92.08 - $124.48 $2.41 Million - $3.26 Million	-26,178 Reduced 11.23%	206,911 $23.2 Million
Q3 2020 Nov 16, 2020	BUY	$66.45 - $92.7 $332,250 - $463,500	5,000 Added 2.19%	233,089 $21.6 Million
Q1 2020 May 15, 2020	BUY	$48.11 - $82.22 $5.05 Million - $8.62 Million	104,871 Added 85.11%	228,089 $13.3 Million
Q2 2019 Aug 14, 2019	BUY	$73.54 - $97.8 $257,390 - $342,300	3,500 Added 2.92%	123,218 $11.6 Million
Q1 2019 May 15, 2019	BUY	$48.7 - $86.6 $1.32 Million - $2.34 Million	27,027 Added 29.16%	119,718 $9.58 Million
Q2 2018 Aug 13, 2018	BUY	$60.96 - $101.18 $243,840 - $404,720	4,000 Added 4.51%	92,691 $5.88 Million
Q1 2018 May 15, 2018	SELL	$73.28 - $102.95 $879,360 - $1.24 Million	-12,000 Reduced 11.92%	88,691 $8.13 Million
Q4 2017 Feb 14, 2018	BUY	$62.91 - $88.32 $1.55 Million - $2.18 Million	24,691 Added 32.49%	100,691 $7.59 Million
Q3 2017 Nov 14, 2017	BUY	$42.37 - $69.67 $3.22 Million - $5.29 Million	76,000	76,000 $5.3 Million

Others Institutions Holding BPMC

# of Institutions

350

Shares Held

60.3M

Call Options Held

2.25M

Put Options Held

1.18M

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.66B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dafna Capital Management LLC with notifications on news.

Account

Dafna Capital Management LLC Blueprint Medicines Corp Transaction History